Arcus raised about $270 million, giving it more cash, but issued 16.4 million shares. The filing does not say how the cash will be used, so these facts point in opposite directions without a clear change to its outlook.
The cash gives Arcus more money to fund its work, but the filing does not say where it will go. Existing owners now own a smaller part of the company. These facts pull in opposite directions, so the filing alone does not change the outlook.
Follow Arcus Biosciences, Inc. (RCUS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RCUS